Search Results for "Cost Of G Csf Drugs"
Matching Channels
Shanghai TASH Biotechnology Co.,Ltd. specializes in peptide development on the basis of high technology. TASH Biotechnology are focusing on custom peptide synthesis, and the research, development...
Matching News
Australia To Cover Cost Of 11 New Drugs, Including Pharmaxis' Bronchitol
Australia's Pharmaceutical Benefits Scheme plans to subsidize the cost of 11 new drugs, an action affecting about 45,000 patients.
Cost of HIV drugs cost less than previous thought, Clinton Foundation study says
"Lack of money can no longer be considered a reason -- or an excuse -- for failing to treat all those with HIV who need drugs to stay alive, following game-changing work about to be published by the C...
Out-of-pocket costs for cancer drugs can vary dramatically depending on whether the medications are administered through pill form or intravenous infusion. Newer oral drugs, which can be taken at home...
CMS proposes higher cost-sharing on Medicaid
States would be able to establish higher cost-sharing levels for non-preferred drugs covered by Medicaid under a proposed rule CMS issued on Monday. For preferred drugs, CMS proposed a maximum out-of-...
Mega-Randomized Clinical Trials for Blockbuster Drugs—Reply
In Reply: Mega-trials for blockbusters are readily feasible. There would be no cost for the government or health care system. Drug production cost to industry (as opposed to sales cost) is negligible....
Cost Offsets and Cost-Effectiveness With Pegylated Drugs
Pegylated drugs have many benefits…Is cost-savings one? Expert Review of Pharmacoeconomics & Outcomes Research
UK cost agency backs drugs for preventing breast cancer
LONDON (Reuters) - British women with a family history of breast cancer could be offered two drugs to try to prevent the disease under draft guidelines published by the country's healthcare cost watch...
High Costs Of Cancer Drugs May Harm Patients, Say Experts
Medscape: High Price Of Cancer Drugs Is Harming Patients The extremely high prices of recent cancer drugs "may be causing harm to patients," a large group of international leukemia experts warns. In...
Matching PubMed Articles
The impact of new cancer drugs in real practice oncology: a monoinstitutional experience.
Urgent solutions range from re-engineering of the macroeconomic basis of cancer costs (e.g. value-based approaches to bend the cost curve and allow cost-saving technologies), greater education of poli...
Pharmacoeconomic considerations in the treatment of multiple sclerosis.
Multiple sclerosis (MS) is a disorder that incurs high costs to individuals, health systems and society as a whole. A growing number of studies have measured the costs of MS and assessed the cost effe...
OBJECTIVE: To estimate the incremental costs to public payers for patients with ankylosing spondylitis (AS) of working age compared with reference subjects from the general population. METHODS: We inv...
Disease-modifying drugs in multiple sclerosis: a review of expenditure in Ireland.
INTRODUCTION: The prevalence of multiple sclerosis (MS) in Ireland is well over the European and global averages and the costs associated with managing this disease are placing a heavy economic burden...
The economic pressures for biosimilar drug use in cancer medicine.
The main rationale for using biosimilar drugs is for cost saving. The market development for biosimilar drugs will therefore depend on the degree to which cost saving measures are required by nations,...
